Haemonetics Corporation (NYSE:HAE) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• According to analysts, Haemonetics Corporation (NYSE:HAE) has a consensus rating of "Moderate Buy", with seven analysts recommending buy and one assigning a strong buy rating.
• Haemonetics reported $1.10 earnings per share for the last quarter, exceeding analyst expectations and generating a revenue of $321.39 million.
• The stock's average one-year price target among brokers is $78.78, while Haemonetics' shares recently opened at $50.54, reflecting a 1.2% decline.

Haemonetics Corporation (NYSE:HAE - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $78.7778.

A number of research firms have recently weighed in on HAE. Citigroup upgraded shares of Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 price target on the stock in a report on Wednesday, July 9th. Mizuho cut their price target on shares of Haemonetics from $90.00 to $70.00 and set an "outperform" rating on the stock in a report on Friday, August 8th. Raymond James Financial lowered shares of Haemonetics from a "strong-buy" rating to an "outperform" rating and lowered their target price for the company from $105.00 to $78.00 in a research note on Monday, August 11th. JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $62.00 target price (down from $85.00) on shares of Haemonetics in a research note on Friday, August 8th. Finally, Barrington Research decreased their price target on shares of Haemonetics from $95.00 to $86.00 and set an "outperform" rating on the stock in a research report on Friday, August 8th.

Haemonetics Stock Down 1.2%

HAE stock opened at $50.54 on Monday. The company has a market cap of $2.43 billion, a price-to-earnings ratio of 15.45, a PEG ratio of 0.93 and a beta of 0.39. The company has a 50 day moving average of $61.19 and a two-hundred day moving average of $64.85. The company has a quick ratio of 1.04, a current ratio of 1.72 and a debt-to-equity ratio of 1.04. Haemonetics has a 12-month low of $49.43 and a 12-month high of $94.99.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share for the quarter, beating analysts' consensus estimates of $1.01 by $0.09. The business had revenue of $321.39 million for the quarter, compared to the consensus estimate of $305.12 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. Haemonetics's revenue for the quarter was down 4.4% on a year-over-year basis. During the same quarter last year, the firm earned $1.02 EPS. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. On average, equities analysts anticipate that Haemonetics will post 4.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Haemonetics

A number of institutional investors have recently modified their holdings of the stock. Quarry LP raised its stake in shares of Haemonetics by 63.4% during the first quarter. Quarry LP now owns 495 shares of the medical instruments supplier's stock worth $31,000 after buying an additional 192 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier's stock worth $31,000 after buying an additional 396 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Haemonetics by 59.4% during the second quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier's stock worth $33,000 after buying an additional 165 shares during the last quarter. UMB Bank n.a. raised its stake in shares of Haemonetics by 91.7% during the second quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier's stock worth $50,000 after buying an additional 320 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC bought a new stake in shares of Haemonetics during the second quarter worth approximately $64,000. 99.67% of the stock is owned by institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.